19 clinical trials found.
-
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma Grade IIIb Follicular Lymphoma transformed lymphoma and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
The purpose of the study is to evaluate the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for patients ...Phase
-
A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
The purpose of the study is to evaluate the activity of a novel triplet combination of rituximab and hyaluronidase human, polatuzumab vedotin, and venetoclax for ...Phase
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma
The purpose of the study is to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with ...Phase
-
A PHASE Ib STUDY EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE (CHP) IN PATIENTS WITH UNTREATED BCL-2 IMMUNOHISTOCHEMISTRY (IHC) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
The purpose of this study is to test two different dosing schedules of an experimental drug called venetoclax. Venetoclax works by blocking a protein in ...Phase
-
GBM Agile Trial
The purpose of the research study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of ...Phase
-
A Pivotal Randomized Open-Label Study of Optune (TTFields 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
The purpose of the study is to test the effectiveness and safety of TTFields given to newly diagnosed glioblastoma patients, concomitantly with radiation therapy and ...Phase
-
A PHASE 1 OPEN-LABEL DOSE FINDING STUDY OF CC-95251 A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRPa ALONE AND IN COMBINATION WITH CETUXIMAB OR RITUXIMAB IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS
The purpose of the study is to look at how your body tolerates CC-95251 and safety of the CC-95251 when administered intravenously (IV) as single ...Phase
-
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine Rituximab High Dose Cytarabine and Acalabrutinib (BR/CR-A) and 3.) Bendamustine Rituximab and Acalabrutinib (BR-A) in Patients = 70 years old with Untreated Mantle Cell Lymphoma
The purpose of the study is to determine the efficacy and tolerability of bendamustine (B), rituximab (R) and high dose cytarabine (C) [(BR/CR] versus ...Phase
-
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
The purpose of this research study is to provide ONC201 to patients with specific forms of brain cancer who cannot access ONC201 by participating in ... -
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
The purpose of the study is to determine the overall response rates as well as safety and tolerability of olaparib in subjects with recurrent/progressive ...Phase
